Tavalisse (fostamatinib) / Rigel Pharmaceuticals, Kissei, JW Pharma, Grifols, Knight Therap, Tanabe Pharma - LARVOL DELTA

Early Use of Fostamatinib in Immune Thrombocytopenia. (PubMed, Adv Ther) - "Fostamatinib demonstrated high effectiveness and acceptable tolerability as second- or third-line therapy for adult ITP in real-world clinical practice."

Clinical • Journal • Cardiovascular • Hematological Disorders • Hypertension • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura • SYK

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease (clinicaltrials.gov) - P1 | N=35 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | N=25 ➔ 35

Enrollment change • Anemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease

Acoustic-prosodic markers in older adults with and without Parkinson's disease. (PubMed, Logoped Phoniatr Vocol) - "Cvint, shimmer, and fosd contributed at a secondary level, with relative relevance varying according to PD severity. Overall, alterations in speech timing constitute the primary acoustic dimension distinguishing PD-related speech changes from age-related effects in this dataset, supporting the descriptive relevance of speech-based acoustic-prosodic analyses obtained from mobile phone recordings in non-invasive research settings."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Early-life susceptibility to Streptococcus pneumoniae is driven by Mincle+ MDSC–mediated immune suppression (ERS 2026) - "Inhibition of this pathway with the clinical Syk inhibitor fostamatinib improved infection outcomes. Together, these findings identify MDSC-mediated immunosuppression as a key determinant of heightened pathogen susceptibility in children and highlight the CPS/Mincle/Syk axis as a promising therapeutic target for pediatric and severe infections."

Myeloid-derived suppressor cells • Infectious Disease • Pneumococcal Infections • Pneumonia • STAT2 • SYK

Evolving Paradigms in the Management of Primary Immune Thrombocytopenia in Adults: From Corticosteroids to Targeted Therapies. (PubMed, Mediterr J Hematol Infect Dis) - "For decades, treatment relied on corticosteroids as first-line therapy, followed by a limited range of second-line options including thrombopoietin receptor agonists (TPO-RAs), rituximab, splenectomy, and, more recently, fostamatinib. Particular attention is given to distinguishing approved therapies from investigational agents by region and date, interpreting heterogeneous trial endpoints with appropriate caution, and integrating disease features, safety considerations, and patient preferences into treatment selection. Although recent phase II and III studies support the biological and clinical promise of several targeted agents, the optimal sequencing and combination of these therapies remain to be defined."

Journal • Review • Fatigue • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura • BTK

Knight Therapeutics Announces Regulatory Approval of TAVALISSE in Colombia (The Globe and Mail) - "Knight launched TAVALISSE in Mexico in May 2026 and expects to launch in Brazil in the fourth quarter of 2026 and in Colombia in the first half of 2027."

Approval • Launch non-US • Immune Thrombocytopenic Purpura • Immunology

Association of CD16hiCD62Llo Neutrophils with Disease Severity and Impact of SYK Inhibition in Sepsis. (PubMed, J Inflamm Res) - "Additionally, purified neutrophils from 20 sepsis patients were stimulated with lipopolysaccharide (LPS), with and without R406 treatment, to assess changes in neutrophil populations and the impact of spleen tyrosine kinase (SYK) inhibition...Finally, ex vivo stimulation of sepsis neutrophils with LPS increased the percentage of CD16hi/CD62Llo population and the shift in this population could be prevented with SYK inhibition. These data suggest that CD16hi/CD62Llo neutrophils may contribute to sepsis pathogenesis and that SYK is a potential therapeutic target that can modulate this neutrophil population, but further mechanistic studies are warranted to establish a causal role in sepsis."

Journal • Critical care • Infectious Disease • Septic Shock • CD33 • MME • SELL • SYK

FcRn Inhibition Reduces T-Cell-Mediated Rejection in a Mouse Model of Lung-Directed AAV Gene Transfer (NACFC 2026) - "Immunomodulatory strategies tested included administration of the FcRn inhibitor efgartimod (200 ?g by i.p. injection on d-2, -1, and + 1 relative to AAV6.2-Luciferase delivery) and SYK inhibition using fostamatinib (10mg/kg delivered by osmotic minipump implanted on d-2)... We demonstrate that both antibodies and T-cells are required to trigger CD8+ mediated rejection of AAV-transduced lung cells. Antibodies likely enhance cross-presentation of capsid antigen by dendritic cells, enabling robust T-cell activation. FcRn inhibition may represent a promising immunomodulatory strategy by both reducing pre-existing antibody titres and directly inhibiting the immune complex cross-presentation."

Preclinical • Gene Therapies • Immunology • CD69 • CD8 • CD80 • ITGAE • ITGAX • SYK

EFFECTS OF FOSTAMATINIB IN HOSPITALIZED PATIENTS WITH COVID-19 INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS (CHEST 2026) - No abstract available

Retrospective data • Review • Infectious Disease • Novel Coronavirus Disease

Platelet SYK promotes solid tumor metastasis via TXA2-mediated immunosuppression. (PubMed, J Thromb Haemost) - "Taken together, our results indicate, that SYK in platelets promotes solid tumor metastasis and tumor immunosuppression. Secretion of TXA2 by platelets is SYK-dependent and can be inhibited by SYK-selective inhibitors, which release anti-tumor CD8+ T cells from TXA2-mediated suppression."

Journal • Colorectal Adenocarcinoma • Colorectal Cancer • Gastrointestinal Disorder • Melanoma • Oncology • Solid Tumor • CD8 • SYK

The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review. (PubMed, Rheumatology (Oxford)) - "We have found a consistent thrombotic burden in high-risk ITP patients on second-line therapy, evident across all examined treatment options, underscoring the pro-thrombotic immune milieu of this population and the need for tailored risk-mitigation strategies."

Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Inflammatory Arthritis • Lupus • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis

Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Not yet recruiting ➔ Recruiting

Enrollment open • Transplant Rejection • Transplantation

Identification of senescence-related genes in diagnosing idiopathic pulmonary fibrosis via integrating bioinformatics analysis and machine learning. (PubMed, PLoS One) - "Collectively, these findings identify CHEK2 as a critical regulator of AEC senescence and IPF development, supporting its potential use as a diagnostic biomarker and therapeutic target. Fostamatinib may represent a candidate therapeutic strategy for IPF by modulating CHEK2-related senescence pathways."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • CHEK2 • TP53

Real-world effectiveness of fostamatinib in patients with immune thrombocytopenia: a single-center retrospective study. (PubMed, Int J Hematol) - "This study demonstrates the real-world effectiveness and safety of fostamatinib in patients with ITP. Platelet count rose soon after fostamatinib initiation, within 1-2 weeks. Fostamatinib may enable reduction or discontinuation of GCs, even in patients with ITP refractory to TPO-RAs."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis • SYK

Second Quarter and Year-to-Date 2026 Financial Update (PRNewswire) - "TAVALISSE net product sales were $47.4 million, an increase of 18% compared to $40.1 million in the same period of 2025."

Sales • Immune Thrombocytopenic Purpura

Post-marketing surveillance of fostamatinib for primary immune thrombocytopenia in Japan: interim analysis. (PubMed, Int J Hematol) - "Further, complete response (platelet count ≥ 100,000/μL) was observed in 135 of 309 patients at 3 months and 128 of 241 patients at 6 months under continuous fostamatinib use. The results of this real-world PMS revealed no new safety concerns and support the effectiveness of fostamatinib in patients with primary ITP."

Journal • P4 data • Cardiovascular • Hematological Disorders • Hepatology • Hypertension • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Network meta-analysis comparing the efficacy of subsequent treatment regimens in primary immune thrombocytopenia patients (ISTH 2026) - "In placebo- controlled studies, Romiplostim showed the highest efficacy, followed by Hetrombopag, Eltrombopag, Fostamatinib, and Rilzabrutinib. In studies using Danazol as the control, ATRA plus danazol had the highest efficacy, followed by Tacrolimus plus danazol and rhTPO plus danazol. In studies using Eltrombopag as the control, the Eltrombopag plus diacerein regimen was more effective than rhTPO. Conclusions These results furnish high-quality evidence to support evidence-based, individualized selection of subsequent therapy for adults with relapsed/refractory primary immune thrombocytopenia. Table or Figure Upload (1) Figure 1.Network meta-analysis comparing the efficacy of subsequent treatment regimens Page 2 DOI*10.1016/j.rpth.2026.104395"

Retrospective data • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Nasal Mucosal Necrosis in a Patient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Case Report and Literature Review. (PubMed, J Clin Med) - "After replacing eltrombopag with fostamatinib (a Syk inhibitor), the nasal lesions improved markedly, with complete mucosal healing. Nasal mucosal necrosis, a rare but serious symptom of secondary APS, requires careful differential diagnosis from IFS or other necrotizing diseases. APS-related vasculopathy should be considered following TPO-RA therapy, particularly if repeat debridement fails to identify an infectious cause."

Journal • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Otorhinolaryngology • Respiratory Diseases • Sinusitis • Systemic Lupus Erythematosus • Thrombocytopenia • SYK

Emerging synthetic drugs for the management of Hidradenitis Suppurativa: a comprehensive update. (PubMed, Expert Opin Pharmacother) - "Currently, only three biologic agents - adalimumab, secukinumab, and bimekizumab - hold regulatory approval for moderate-to-severe HS...Mechanistic classes discussed include Janus kinase (JAK) inhibitors (povorcitinib, upadacitinib, ruxolitinib), TYK2 inhibitors (brepocitinib, ropsacitinib, deucravacitinib), PDE-4 inhibitors (apremilast, orismilast, roflumilast), BTK/SYK inhibitors (remibrutinib, fostamatinib), IRAK-4 inhibitors (zimlovisertib), and HSP-90 inhibitors (RGRN-305)...The emergence of topical JAK inhibitors (ruxolitinib cream) for milder HS and the progression of BTK inhibitors (remibrutinib) to Phase 3 trials signal a broadening treatment landscape. Personalized selection of synthetic drugs versus biologics - informed by patient comorbidities, disease phenotype, and biomarkers - will be involved in next-generation HS management."

Journal • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • IRAK4 • JAK1 • SYK • TYK2

EMPATHI Study: Real-World Evidence on Adult ITP Management, Treatment Response, and Patient Burden in Spain (ISTH 2026) - "TPO ‑ RAs remain the preferred option in second ‑ line treatment, while rituximab plays a residual role. The most frequently used average weekly doses are: eltrombopag 350mg (72%), avatrombopag 140mg (72%), fostamatinib 1400mg (52%), and romiplostim 3-4 μg/kg (40% each)...Current Treatment Patterns by Line of Therapy Page 2 Table or Figure Upload (2) Figure 1. Response rate of ITP patients per product and line according to the GEPTI 2023 guidelines DOI*10.1016/j.rpth.2026.104431"

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Dyslipidemia • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Metabolic Disorders • Pulmonary Arterial Hypertension • Thrombocytopenia • Thrombocytopenic Purpura

CHARACTERIZATION OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN SPAIN. PRELIMINARY RESULTS FROM RESTI: SPANISH REGISTRY OF PRIMARY IMMUNE THROMBOCYTOPENIA (ISTH 2026) - "Corticosteroids were the most frequently used first-line therapy (95%), with prednisone (67.3%) and dexamethasone (39.7%) being the most commonly prescribed agents. Methylprednisolone (13.2%) and deflazacort (0.9%) were used less frequently...Second-line and subsequent therapies were widely used, particularly thrombopoietin receptor agonists, including eltrombopag (45.4%), avatrombopag (37.9%), and romiplostim (28.8%). Fostamatinib was prescribed in 12.1% of patients, and rituximab in 10%...Ultimately, RESTI aims to support harmonization of clinical practice and to serve as a reference framework for future national and international collaborative studies. Table or Figure Upload (1) Page 3 Table or Figure Upload (2) DOI*10.1016/j.rpth.2026.104420"

Clinical • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura

Comparison of different SYK-inhibitors in platelet-rich plasma (ISTH 2026) - "Methods Platelet-rich plasma (PRP) from healthy donors (n=3; technical duplicates) was incubated with SYK inhibitors (Sovleplenib, P505-15, R406, BI2494) at 100 µM-100 nM...Saracatinib (pan-Src-family kinase inhibitor) and Pirtobrutinib (BTK inhibitor) served as comparators...These findings provide a baseline reference for subsequent studies in CKD patient samples to define how CKD- associated inflammation modifies SYK-dependent platelet responses. Table or Figure Upload (1) Page 2 DOI*10.1016/j.rpth.2026.105268"

Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Inflammation • Nephrology • Renal Disease • Thrombosis • SYK

Aging-driven transcriptional programs in diabetic kidney disease: multi-omics discovery of diagnostic biomarkers and drug-repurposing targets. (PubMed, Clin Epigenetics) - "In this study, we identified age-related hub genes, constructed a reliable diagnostic signature, and suggested SYK-fostamatinib and APOC3-selexipag as potential drug-repurposing candidates for DKD, which requires further experimental and clinical validation."

Biomarker • Journal • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Nephrology • Renal Disease • EGF • RB1 • RPA1 • SYK

Disruption of carbon metabolism by the hepatic mononuclear phagocytic system drives liver injury in a mouse model of severe dengue. (PubMed, J Hepatol) - "Fostamatinib demonstrated significant efficacy in mitigating liver injury induced by DENV infection, while concurrently alleviating inflammatory responses and ameliorating carbon metabolism disorders."

Journal • Preclinical • Dengue Fever • Hepatology • Infectious Disease • Inflammation • Liver Failure • Metabolic Disorders • Oncology • BTK

Immune thrombocytopenia: Evolving mechanistic understanding and clinical development of new therapies. (PubMed, Tzu Chi Med J) - "Although corticosteroids, intravenous immunoglobulin, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonists have constituted the therapeutic foundation for decades, these approaches remain limited by transient responses, toxicity, and insufficient disease modification...Bruton tyrosine kinase (BTK) inhibitors (rilzabrutinib and orelabrutinib) modulate B-cell activation and macrophage effector pathways; spleen tyrosine kinase inhibitors (fostamatinib) block Fcγ receptor-mediated phagocytosis, neonatal Fc receptor inhibitors (efgartigimod and rozanolixizumab) accelerate IgG catabolism and rapidly reduce pathogenic autoantibody burden; and complement inhibition (sutimlimab) provides a rational strategy for patients in whom classical pathway activation contributes to refractory disease. Collectively, these agents represent the most significant expansion of the ITP treatment landscape in decades, offering steroid-sparing options and enabling more..."

Journal • Review • Hematological Disorders • Immune Thrombocytopenic Purpura • Immunology • Thrombocytopenia • Thrombocytopenic Purpura